Bio-Rad Laboratories (BIO-B) EBT (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of EBT data on file, last reported at -$689.8 million in Q1 2026.

• EBT for Q1 2026 came in at -$689.8 million, down 927.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.3 million (up 108.08% YoY), and the FY2025 annual result was $995.5 million, up 142.5% from the prior year.
• EBT retreated to -$689.8 million in Q1 2026 per BIO-B's latest filing, from $929.2 million in the prior quarter.
• Over five years, EBT peaked at $1.1 billion in Q4 2022 and troughed at -$4.4 billion in Q1 2022.
• A 5-year average of -$446.5 million and a median of $83.4 million in 2025 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2026: EBT surged 528.45% in 2024, then sank 927.1% in 2026.
• A 5-year view of EBT shows it stood at $1.1 billion in 2022, then sank by 60.75% to $428.4 million in 2023, then tumbled by 312.16% to -$908.9 million in 2024, then surged by 202.23% to $929.2 million in 2025, then sank by 174.24% to -$689.8 million in 2026.
• Business Quant data shows BIO-B's EBT at -$689.8 million in Q1 2026, $929.2 million in Q4 2025, and -$431.1 million in Q3 2025.